To include your compound in the COVID-19 Resource Center, submit it here.

Analyst picks & changes

Amgen Inc.

(AMGN)

Genetics Institute Inc.

(GENIZ)

Genzyme Corp.

(GENZ)

Immunex Corp.

(IMNX)

An FDA advisory panel decision last week not to recommend approval of IMNX's

Leukine

GM-CSF for the broad indication of chemotherapy-induced neutropenia (see BioCentury Extra, April 11) spurred a spate of comments on the consequences for several companies.

Joyce Lonergan of Cowen & Co. said she expects IMNX shares to be under significant

Read the full 676 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE